Earnings summaries and quarterly performance for Inmune Bio.
Executive leadership at Inmune Bio.
Board of directors at Inmune Bio.
Research analysts who have asked questions during Inmune Bio earnings calls.
George Farmer
Scotiabank
3 questions for INMB
Also covers: ABSI, ADAP, KURA +7 more
Thomas Shrader
BTIG
3 questions for INMB
Also covers: ABOS, ALEC, ARCT +8 more
Denis Reznik
Raymond James
2 questions for INMB
Also covers: AQST, PCRX, VERU
Gary Nachman
Raymond James
2 questions for INMB
Also covers: ABBV, ACHV, ADMA +9 more
James Molloy
Alliance Global Partners
2 questions for INMB
Also covers: ABEO, ACXP, AIM +11 more
Boris Tolkachev
Freedom Broker
1 question for INMB
Also covers: ACHV
Elemer Piros
Rodman & Renshaw
1 question for INMB
Also covers: BRTX, CMPS, CRBP +2 more
Jenny Kim
BTIG
1 question for INMB
Joel Beatty
Baird
1 question for INMB
Also covers: ACAD, ALKS, AMLX +11 more
Laura Suriel
Alliance Global Partners
1 question for INMB
Also covers: BCDA, GOVX, IMNN
Matthew Vinita
AGP
1 question for INMB
Recent press releases and 8-K filings for INMB.
INmune Bio Inc. enters into Sales Agreement for up to $65 million in common stock sales
INMB
- INmune Bio Inc. entered into a Sales Agreement with A.G.P./Alliance Global Partners on December 19, 2025.
- Under this agreement, the company may offer and sell up to $65,000,000 of shares of its common stock through A.G.P. as a sales agent.
- The company will pay A.G.P. a commission of 3.0% of the aggregate gross proceeds from each sale of common stock.
- The sales will be conducted as "at the market offerings" pursuant to an effective shelf registration statement.
6 hours ago
INmune Bio extends Rights Agreement expiration
INMB
Takeover Bid
- INmune Bio Inc. (INMB) entered into Amendment No. 5 to its Rights Agreement on December 5, 2025.
- This amendment extends the expiration of the Rights Agreement to December 31, 2026.
- The Rights Agreement will now automatically renew for successive one-year terms after December 31, 2026, unless the Company's Board of Directors determines not to extend it.
Dec 8, 2025, 9:00 PM
Inmune Bio Inc. Presents Investor Update on Pipeline and Milestones
INMB
New Projects/Investments
Product Launch
Guidance Update
- Inmune Bio Inc. (INMB) released an investor presentation on November 10, 2025, detailing its clinical-stage pipeline and upcoming milestones.
- The company's CORDStrom program for RDEB has completed Phase 2, with Marketing Authorization Application (MAA) in the UK expected mid-2026 and Biologics License Application (BLA) in the US by late-2026.
- The XPro program for Early Alzheimer's, having completed Phase 2 with zero cases of ARIA, is scheduled for an End-of-Phase-2 FDA meeting in Q1 2026 and Phase 3 initiation in 2027.
- As of October 14, 2025, Inmune Bio Inc. reported a market capitalization of $50 million and $30 million in cash, with approximately 26.5 million shares outstanding.
Nov 10, 2025, 10:13 PM
INmune Bio Reports Q3 2025 Financial Results and Provides Program Updates
INMB
Earnings
New Projects/Investments
Guidance Update
- INmune Bio reported a net loss of $6.5 million for the third quarter of 2025, an improvement from $12.1 million in the comparable period of 2024. The company held $27.7 million in cash and cash equivalents as of September 30, 2025, which is expected to fund operations into Q4 2026.
- The Cordstrom program, targeting recessive dystrophic epidermolysis bullosa (RDEB), is preparing for marketing authorization applications, with submissions anticipated in the UK by mid-2026 and the US a few months later, following demonstrated benefits in clinical trials.
- For the EXPRO program (Alzheimer's disease), Phase 2 Mindful trial results were submitted for peer-reviewed publication, indicating positive outcomes in patients with higher baseline inflammation and no ARIA-related safety signals. The company anticipates an FDA decision on an accelerated pathway and end-of-Phase 2 meeting minutes in Q1 2026.
- The Incuboom program for prostate cancer successfully completed its Phase 2 trial in 2023, meeting its primary and two secondary endpoints.
Oct 30, 2025, 8:30 PM
INmune Bio Inc. Announces Third Quarter 2025 Results and Business Update
INMB
Earnings
Management Change
- INmune Bio Inc. reported a net loss attributable to common stockholders of approximately $6.5 million for the quarter ended September 30, 2025, compared to $12.1 million during the same period in 2024.
- Research and development expenses for Q3 2025 were approximately $4.9 million, a decrease from $10.1 million in Q3 2024, while general and administrative expenses increased to approximately $2.5 million from $2.2 million.
- As of September 30, 2025, the company had approximately $27.7 million in cash and cash equivalents.
- Business updates include the CORDStrom™ platform being on target for MAA submission mid-2026, positive results from the XPro™ Phase 2 MINDFuL trial in Alzheimer's Disease, and the INKmune® CARE-PC trial meeting its primary and two secondary endpoints.
- David Moss was appointed President & Chief Executive Officer, and Cory Ellspermann was appointed CFO.
Oct 30, 2025, 8:15 PM
INmune Bio Submits Phase 2 MINDFuL Trial Results for Alzheimer's Disease
INMB
New Projects/Investments
- INmune Bio, Inc. announced on September 29, 2025, the submission of a manuscript detailing the results of its Phase 2 MINDFuL trial for XPro™ in early Alzheimer’s disease to npj Dementia, a Nature Portfolio journal.
- The study did not meet its primary endpoint in the overall population but showed a promising signal in a prespecified subgroup of patients with both amyloid pathology and a high inflammatory burden.
- In this subgroup, XPro™ demonstrated consistent positive trends across cognitive, neuropsychiatric, and biological endpoints, along with a favorable safety profile characterized by the complete absence of amyloid-related imaging abnormalities (ARIA).
- The company anticipates receiving regulatory feedback from the FDA in the first quarter of 2026.
Sep 30, 2025, 8:05 PM
Intelligent Bio Solutions Inc. Reports Fiscal 2025 Results and Progress on U.S. Market Expansion
INMB
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Intelligent Bio Solutions Inc. reported fiscal Q4 2025 revenue of $843,884, representing a 16% increase year-on-year and quarter-on-quarter, driven by increased demand for drug testing cartridges.
- For the full fiscal year ended June 30, 2025, the company reported a net loss attributable to Intelligent Bio Solutions Inc. of $(10,568,733) and a net loss per share of $(2.00).
- The company advanced efforts to secure U.S. FDA 510(k) clearance for its opiate test system for codeine, which is a strategic priority to expand beyond Forensic Use Only settings in the U.S. market.
- Operational highlights include securing 115 new accounts throughout the year and strengthening its intellectual property with the addition of a sixth U.S. patent.
Aug 15, 2025, 12:30 PM
INmune Bio to publish video detailing XPro™ MINDFuL trial findings
INMB
New Projects/Investments
- INmune Bio (INMB) announced it will publish a video on its YouTube Channel on Thursday, July 31, 2025, at 4 PM ET, detailing additional findings from the Phase 2 MINDFuL trial evaluating XPro™ for Alzheimer’s disease.
- The findings were presented at the Alzheimer’s Association International Conference (AAIC) on Tuesday, July 29, 2025.
- The MINDFuL trial is a double-blind, Phase 2 proof-of-concept study examining XPro™'s potential to slow cognitive decline in early-stage Alzheimer’s disease by targeting neuroinflammation.
- In a subpopulation of patients with amyloid-beta pathology and at least two blood biomarkers of inflammation, XPro™ demonstrated a consistent benefit after six months of treatment.
- XPro™ showed a beneficial signal across multiple measures, including cognition, memory, neuropsychiatric, and biomarkers, and exhibited a favorable safety profile with no cases of ARIA or deaths.
Jul 29, 2025, 12:00 AM
INmune Bio to Present Phase 2 MINDFuL Trial Findings for XPro™ at AAIC
INMB
New Projects/Investments
- INmune Bio Inc. announced that additional analyses from its Phase 2 MINDFuL trial for XPro™, a treatment for Alzheimer's disease, will be presented at the Alzheimer’s Association International Conference in Toronto, Canada, on July 29, 2025, between 2:00 and 3:30 PM ET.
- While the primary endpoint was not met in the overall study population, the trial demonstrated consistent benefits of XPro™ after 6 months in a subpopulation of patients with biomarker-confirmed amyloid-beta pathology and at least two blood biomarkers of systemic inflammation.
- The company anticipates submitting a publication of the MINDFuL Phase 2 study results by mid-August and is seeking a strategic partnership to accelerate the further development of XPro™.
Jul 25, 2025, 12:00 AM
INmune Bio Reports Phase 2 MINDFUL Trial Results for Alzheimer's Drug Xpro
INMB
New Projects/Investments
M&A
- INmune Bio's MINDFUL Phase 2 trial for Xpro in early Alzheimer's disease found the drug to be safe and effective in preventing cognitive decline in a predefined subgroup of 150 biologically defined Alzheimer's disease patients with two or more biomarkers of inflammation. The primary endpoint was not met in the overall modified intent-to-treat population.
- In the effective subgroup, Xpro showed clinically important effect sizes on cognition (EMAC: 0.27), behavior (MPI 12: 0.23), and disease-relevant blood biomarkers (p tau two seventeen: 0.2). The most common adverse event was injection site reactions, which occurred in 80% of Xpro patients but were manageable.
- The company plans to explore partnering opportunities for Xpro and will conduct End of Phase 2 meetings with the FDA before year-end to seek agreement on EMAC as a primary cognitive endpoint for future trials.
- INmune Bio also has the financial resources to continue developing its Cordstrom and Inkmune cell therapy programs, with regulatory filings for Cordstrom expected by the first half of next year and additional Inkmune data by the end of this year.
Jun 30, 2025, 1:51 PM
Quarterly earnings call transcripts for Inmune Bio.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more